PICK1 inhibits the E3 ubiquitin ligase activity of Parkin and reduces its neuronal protective effect

Significance Parkinson’s disease (PD) is the second most common neurodegenerative disorder. It is characterized by progressive deterioration of motor function caused by loss of dopamine-producing neurons. Currently, there is no treatment that could stop the progress of the disease. Loss-of-function mutations in Parkin account for ∼50% of early onset PD. Parkin functions as an E3 ubiquitin ligase that exhibits multiple protective roles especially in dopaminergic neurons. Here, we demonstrate that PICK1 directly binds to Parkin. PICK1 is a potent endogenous inhibitor of Parkin’s E3 ubiquitin ligase activity and blocks Parkin’s protective functions. Conversely, knockout of PICK1 enhances the neuroprotective effect of Parkin. Thus, the reduction of PICK1 may provide a therapeutic target for the treatment of PD. Parkin functions as a multipurpose E3 ubiquitin ligase, and Parkin loss of function is associated with both sporadic and familial Parkinson’s disease (PD). We report that the Bin/Amphiphysin/Rvs (BAR) domain of protein interacting with PRKCA1 (PICK1) bound to the really interesting new gene 1 (RING1) domain of Parkin and potently inhibited the E3 ligase activity of Parkin by disrupting its interaction with UbcH7. Parkin translocated to damaged mitochondria and led to their degradation in neurons, whereas PICK1 robustly inhibited this process. PICK1 also impaired the protective function of Parkin against stresses in SH-SY5Y cells and neurons. The protein levels of several Parkin substrates were reduced in young PICK1-knockout mice, and these mice were resistant to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated toxicity. Taken together, the results indicate that PICK1 is a potent inhibitor of Parkin, and the reduction of PICK1 enhances the protective effect of Parkin.

[1]  Bryan L Roth,et al.  Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons* , 2003, Journal of Biological Chemistry.

[2]  Kalle Gehring,et al.  Structure of Parkin Reveals Mechanisms for Ubiquitin Ligase Activation , 2013, Science.

[3]  Bonifati,et al.  Association between early-onset Parkinson's disease and mutations in the parkin gene. , 2000, The New England journal of medicine.

[4]  Penny A. MacDonald,et al.  Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. , 2007, Molecular biology of the cell.

[5]  Michael Lazarou,et al.  PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding , 2013, The Journal of cell biology.

[6]  Apolipoprotein E genotype in familial Parkinson's disease. The French Parkinson's Disease Genetics Study Group. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[7]  D. Komander,et al.  Mechanism of phospho-ubiquitin induced PARKIN activation , 2015, Nature.

[8]  Nobutaka Hattori,et al.  14‐3‐3η is a novel regulator of parkin ubiquitin ligase , 2006, The EMBO journal.

[9]  K. Lim,et al.  Loss of locus coeruleus neurons and reduced startle in parkin null mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Takashi Uehara,et al.  Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Kay Hofmann,et al.  Selective autophagy: ubiquitin-mediated recognition and beyond , 2010, Nature Cell Biology.

[12]  Zishan Wang,et al.  Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's Disease , 2017, Parkinson's disease.

[13]  K. Winklhofer,et al.  Inactivation of Parkin by Oxidative Stress and C-terminal Truncations , 2003, Journal of Biological Chemistry.

[14]  T. Dawson,et al.  Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration , 2015, Proceedings of the National Academy of Sciences.

[15]  E. Olson,et al.  Specific Interaction of the PDZ Domain Protein PICK1 with the COOH Terminus of Protein Kinase C-α* , 1997, The Journal of Biological Chemistry.

[16]  S. Snyder,et al.  Sulfhydration mediates neuroprotective actions of parkin , 2013, Nature Communications.

[17]  S. Lipton,et al.  Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation , 2011, Molecular Neurodegeneration.

[18]  Olga Pletnikova,et al.  Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. , 2005, Human molecular genetics.

[19]  Cong Han,et al.  Probes of ubiquitin E3 ligases enable systematic dissection of parkin activation. , 2016, Nature chemical biology.

[20]  Ted M. Dawson,et al.  MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity , 2007, Neurobiology of Disease.

[21]  R. Huganir,et al.  Calcium-Permeable AMPA Receptor Plasticity Is Mediated by Subunit-Specific Interactions with PICK1 and NSF , 2005, Neuron.

[22]  T. Dawson,et al.  The role of parkin in familial and sporadic Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[23]  R. Palmiter,et al.  Parkin-deficient mice are not a robust model of parkinsonism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[25]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[26]  M. Mouradian,et al.  Parkin Accumulation in Aggresomes Due to Proteasome Impairment* , 2002, The Journal of Biological Chemistry.

[27]  T. Dawson,et al.  PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease , 2011, Cell.

[28]  I. Martin,et al.  Recent advances in the genetics of Parkinson's disease. , 2011, Annual review of genomics and human genetics.

[29]  R. Huganir,et al.  PICK1–ICA69 Heteromeric BAR Domain Complex Regulates Synaptic Targeting and Surface Expression of AMPA Receptors , 2007, The Journal of Neuroscience.

[30]  R. Youle,et al.  Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.

[31]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[32]  M. Vila,et al.  MPTP: a review of its mechanisms of neurotoxicity , 2001, Clinical Neuroscience Research.

[33]  Santiago Canals,et al.  Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. , 2003, Human molecular genetics.

[34]  J. Troncoso,et al.  Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function , 2010, Proceedings of the National Academy of Sciences.

[35]  Ted M. Dawson,et al.  Parkin Plays a Role in Sporadic Parkinson's Disease , 2013, Neurodegenerative Diseases.

[36]  R. Palmiter,et al.  Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity , 2005, BMC Neuroscience.

[37]  R. Huganir,et al.  Clustering of AMPA Receptors by the Synaptic PDZ Domain–Containing Protein PICK1 , 1999, Neuron.

[38]  H. Walden,et al.  Regulation of Parkin E3 ubiquitin ligase activity , 2012, Cellular and Molecular Life Sciences.

[39]  Scott R. Kennedy,et al.  Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress , 2015, Neuron.

[40]  A. Abeliovich,et al.  Parkin Is a Component of an SCF-like Ubiquitin Ligase Complex and Protects Postmitotic Neurons from Kainate Excitotoxicity , 2003, Neuron.

[41]  Wai Hung Tsang,et al.  ICA1L forms BAR-domain complexes with PICK1 and is crucial for acrosome formation in spermiogenesis , 2015, Journal of Cell Science.

[42]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[43]  Atsushi Tanaka,et al.  PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.

[44]  Hongjun Song,et al.  Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death , 2005, The Journal of Neuroscience.

[45]  David S. Park,et al.  BAG5 Inhibits Parkin and Enhances Dopaminergic Neuron Degeneration , 2004, Neuron.

[46]  T. Dawson,et al.  Response to Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function" , 2005, Science.